viruslik
particl
vlp
rapidli
develop
influenza
viru
genet
sequenc
order
suppli
vaccin
onset
pandem
safeti
immunogen
one
two
dose
recombin
influenza
vlp
vaccin
evalu
twostag
phase
random
doubleblind
placebocontrol
studi
conduct
healthi
adult
year
age
pandem
mexico
part
subject
random
four
treatment
group
g
g
g
hemagglutinin
ha
vlp
vaccin
placebo
vaccin
day
apart
sera
collect
day
hemagglutin
inhibit
hai
test
review
safeti
immunogen
data
part
addit
subject
immun
singl
dose
g
vlp
vaccin
n
placebo
n
assess
safeti
part
b
result
show
vlp
vaccin
safe
welltoler
system
solicit
event
similar
placebo
vlp
vaccin
group
vaccinerel
seriou
advers
event
dose
respons
trend
solicit
local
advers
event
observ
higher
incid
local
pain
swell
tender
red
report
higher
vlp
dose
group
g
g
compar
placebo
g
vlp
group
follow
vaccin
although
major
local
ae
mild
sever
dose
trend
event
moder
greater
sever
also
note
solicit
event
vlp
vaccin
group
demonstr
robust
hai
immun
respons
singl
vaccin
high
rate
seroprotect
hai
titer
subject
subject
seroneg
time
immun
hai
geometr
mean
titer
gmt
geometr
mean
ratio
gmr
seroconvers
rate
also
statist
higher
vlp
group
compar
placebo
postbaselin
time
point
base
data
addit
clinic
trial
develop
evalu
influenza
vaccin
candid
antigen
manufactur
use
spodoptera
frugiperda
baculovirusbas
vlp
technolog
viruslik
particl
vlp
rapidli
develop
influenza
viru
genet
sequenc
order
suppli
vaccin
onset
pandem
safeti
immunogen
one
two
dose
recombin
influenza
vlp
vaccin
evalu
twostag
phase
random
doubleblind
placebocontrol
studi
conduct
healthi
adult
year
age
pandem
mexico
part
subject
random
four
treatment
group
g
g
g
hemagglutinin
ha
vlp
vaccin
placebo
vaccin
day
apart
sera
collect
day
hemagglutin
inhibit
hai
test
review
safeti
immunogen
data
part
addit
subject
immun
singl
dose
g
vlp
vaccin
n
placebo
n
assess
safeti
part
b
result
show
vlp
vaccin
safe
welltoler
system
solicit
event
similar
placebo
vlp
vaccin
group
vaccinerel
seriou
advers
event
dose
respons
trend
solicit
local
advers
event
observ
higher
incid
local
pain
swell
tender
red
report
higher
vlp
dose
group
g
g
compar
placebo
g
vlp
group
follow
vaccin
although
major
local
ae
mild
sever
dose
trend
event
moder
greater
sever
also
note
solicit
event
vlp
vaccin
group
demonstr
robust
hai
immun
respons
singl
vaccin
high
rate
seroprotect
hai
titer
subject
subject
seroneg
time
immun
hai
geometr
mean
titer
gmt
geometr
mean
ratio
gmr
seroconvers
rate
also
statist
higher
vlp
group
compar
placebo
postbaselin
time
point
base
data
addit
clinic
trial
develop
evalu
influenza
vaccin
candid
antigen
manufactur
use
spodoptera
frugiperda
baculovirusbas
vlp
technolog
influenza
pandem
provid
seriou
challeng
global
health
vaccin
infrastructur
us
public
health
expert
review
nation
global
respons
pandem
outbreak
conclud
nonegg
base
recombin
influenza
vaccin
pursu
develop
mani
shortfal
embryon
eggbas
influenza
vaccin
manufactur
system
recombin
insect
cell
produc
viruslik
particl
manufactur
emerg
one
technolog
potenti
meet
challeng
pose
influenza
pandem
recombin
influenza
vaccin
develop
includ
hemagglutinin
ha
subunit
vaccin
viruslik
particl
vlp
vaccin
influenza
vlp
made
coexpress
influenza
ha
neuraminidas
na
matrix
protein
assembl
envelop
particl
mimic
morpholog
influenza
viru
contain
genet
materi
noninfecti
influenza
ha
na
gene
synthes
clone
baculoviru
use
infect
spodoptera
frugiperda
insect
cell
virusencod
protein
express
within
cell
assembl
bud
viruslik
particl
mimick
viru
structur
express
relev
epitop
particl
empti
viral
genet
materi
vlp
produc
insect
cellderiv
vaccin
use
extens
preclin
set
shown
induc
function
protect
antibodi
season
pandem
influenza
pathogen
recombin
influenza
vlp
vaccin
develop
novavax
inc
rockvil
md
shown
induc
protect
ferret
immun
season
avian
highli
pathogen
pandem
pandem
influenza
strain
recombin
vlpparticl
vaccin
shown
protect
viral
pathogen
sever
acut
respiratori
syndrom
viru
sar
respiratori
syncyti
viru
rsv
recombin
trival
influenza
vlp
vaccin
genet
engin
ha
na
gene
influenza
b
recommend
strain
influenza
season
welltoler
immunogen
phase
clinic
trial
licens
vlp
vaccin
vaccin
develop
human
papilloma
viru
produc
insect
manufactur
platform
indic
vlp
technolog
repres
proven
approach
immun
novel
influenza
triplereassort
viru
swine
human
avian
gene
first
identifi
april
caus
human
respiratori
diseas
mexico
june
almost
confirm
case
report
countri
world
health
organ
declar
influenza
pandem
unit
state
us
center
diseas
control
prevent
cdc
recommend
like
viru
use
monoval
vaccin
pandem
well
flu
season
result
report
meet
indic
pandem
influenza
vaccin
elicit
potenti
protect
antibodi
respons
high
proport
older
children
adult
within
week
administr
singl
dose
vaccin
efficaci
studi
inactiv
vaccin
confirm
vaccin
protect
hemagglutin
inhibit
hai
seroprotect
predict
prevent
influenza
infect
ill
exampl
studi
china
children
adult
immun
splitvirion
vaccin
effect
prevent
confirm
influenza
infect
schoolag
children
spite
success
develop
immunogen
efficaci
pandem
influenza
vaccin
first
dose
vaccin
avail
us
octob
month
epidem
reach
us
mexico
pandem
first
recogn
april
mexico
obtain
licens
vaccin
start
vaccin
program
novemb
end
second
pandem
wave
confirm
case
death
occur
august
report
us
presid
council
advisor
scienc
technolog
review
us
respons
conclud
vaccin
made
recombin
dna
technolog
use
genet
sequenc
prioriti
develop
technolog
could
potenti
reduc
time
requir
suppli
vaccin
anoth
influenza
pandem
occur
thu
clinic
evalu
safeti
immunogen
insect
cellproduc
influenza
vlp
vaccin
import
step
toward
achiev
goal
report
safeti
immunogen
recombin
vlp
vaccin
assess
adult
year
old
midst
pandem
mexico
first
stage
trial
safeti
immunogen
evalu
subject
immun
day
g
g
g
vlp
vaccin
compar
placebo
second
stage
assess
safeti
larger
number
subject
random
receiv
singl
g
dose
vlp
vaccin
placebo
influenza
vlp
produc
spodoptera
frugiperda
lepidoptera
fall
armyworm
cell
infect
recombin
insect
baculoviru
autographa
californica
nuclear
polyhedrosi
viru
acnpv
express
ha
na
gene
ha
na
protein
sequenc
deriv
influenza
genbank
access
number
respect
protein
sequenc
avian
influenza
genbank
access
number
influenza
gene
codon
optim
express
insect
cell
biochem
synthes
insert
baculoviru
transfer
vector
invitrogen
calsbad
ca
clone
escherichia
coli
ha
na
gene
transcript
control
baculoviru
acmnpv
polyhedrin
promot
end
poli
sequenc
end
recombin
baculoviru
contain
three
influenza
gene
gener
use
bactobac
baculoviru
express
system
invitrogen
recombin
bacmid
dna
purifi
transfect
insect
cell
singl
recombin
baculoviru
express
ha
na
identifi
plaquepurifi
amplifi
use
manufactur
influenza
vlp
cgmp
manufactur
recombin
influenza
vlp
conduct
l
wave
bioreactor
ge
healthcar
cell
infect
recombin
baculoviru
vlp
harvest
h
use
presteril
dispos
tangenti
flow
filtrat
tff
assembl
clarif
concentr
diafiltr
concentr
vlp
separ
host
contamin
baculovirus
nucleic
acid
use
ion
exchang
chromatographi
concentr
ultrafiltr
inactiv
residu
baculoviru
beta
propiolacton
final
purif
accomplish
follow
step
gel
filtrat
chromatographi
sucros
gradient
ultracentrifug
diafiltr
pb
filtrat
steril
purifi
vlp
store
c
consid
stabl
store
temperatur
least
year
particl
size
purifi
vlp
measur
dynam
light
scatter
malvern
instrument
puriti
scan
densitometri
sdspage
gel
ha
content
purifi
vlp
measur
use
singl
radial
immunodiffus
srid
assay
base
refer
standard
us
food
drug
administr
center
biolog
evalu
research
cber
two
separ
lot
manufactur
describ
use
separ
part
part
b
studi
describ
purifi
influenza
vlp
pleomorph
larg
spheric
envelop
particl
shown
dynam
light
scatter
transmiss
electron
microscopi
mean
particl
diamet
nm
ha
na
composit
measur
scan
densitometri
avian
influenza
use
place
nativ
increas
yield
influenza
vlp
vaccin
formul
contain
g
g
g
recombin
ha
per
ml
dose
measur
use
srid
assay
vaccin
neutral
ph
phosphat
buffer
formul
fill
individu
steril
vial
inject
phase
random
doubleblind
placebocontrol
studi
design
evalu
safeti
toler
immunogen
dose
level
g
g
g
ha
pandem
influenza
vlp
vaccin
compar
placebo
healthi
adult
age
year
studi
conduct
two
part
part
design
evalu
safeti
immunogen
influenza
vlp
vaccin
dose
rang
select
dose
use
expand
safeti
evalu
part
b
part
subject
randomli
assign
one
four
treatment
group
approxim
ratio
g
g
g
vlp
vaccin
placebo
group
receiv
two
intramuscular
im
inject
studi
vaccin
day
apart
fig
first
subject
enrol
enrol
halt
safeti
review
data
safeti
monitor
board
dsmb
conduct
dsmb
compos
intern
expert
field
vaccinolog
epidemiolog
biostatist
infecti
diseas
provid
independ
safeti
oversight
studi
conduct
signific
safeti
concern
identifi
review
enrol
continu
subject
enrol
part
base
interim
safeti
immunogen
analysi
addit
activ
placebo
subject
enrol
part
b
studi
receiv
singl
inject
day
placebo
g
vlp
second
lot
vaccin
fig
elig
subject
year
age
healthi
acut
diseas
day
vaccin
defin
moder
sever
ill
without
fever
c
immun
live
vaccin
within
four
week
inactiv
vaccin
within
two
week
receiv
vlp
vaccin
women
childbear
potenti
requir
neg
pregnanc
test
time
screen
vaccin
subject
provid
sign
inform
consent
prior
studi
procedur
perform
subject
observ
min
vaccin
reactogen
safeti
evalu
addit
safeti
assess
perform
inclin
visit
ie
day
part
day
part
b
telephon
contact
visit
ie
monthli
day
visit
month
follow
second
vaccin
day
part
day
visit
monthli
day
visit
month
follow
vaccin
day
review
ae
seriou
ae
sae
signific
new
medic
condit
snmc
concomit
medic
also
part
subject
maintain
symptom
diari
seven
day
follow
vaccin
daili
record
solicit
event
se
se
measur
includ
bodi
temperatur
chill
muscl
pain
joint
pain
diarrhea
nausea
vomit
headach
fatigu
cough
difficulti
breath
difficulti
swallow
hoars
chest
tight
sore
throat
red
eye
facial
swell
system
reaction
local
pain
bruis
tender
red
swell
inject
site
reaction
ae
code
accord
meddra
advers
event
dictionari
version
grade
sever
use
standard
scale
vaccineemerg
ae
defin
start
worsen
vaccin
administr
vaccinerel
ae
defin
ae
possibl
relat
studi
vaccin
immunogen
assess
conduct
part
sera
collect
baselin
prior
immun
day
subject
studi
assign
treatment
accord
blind
random
scheme
gener
statistician
icon
clinic
research
part
subject
alloc
one
four
treatment
group
ratio
g
g
g
novel
influenza
vlp
vaccin
placebo
part
b
subject
alloc
ratio
placebo
activ
receiv
placebo
g
dose
vlp
vaccin
minimum
inclus
subject
overal
part
b
combin
vlp
vaccin
safeti
cohort
part
power
achiev
lower
bound
criteria
seroconvers
seroprotect
sampl
size
subject
per
group
entir
vlp
safeti
cohort
subject
minimum
given
event
rate
probabl
observ
one
ae
immunogen
analys
geometr
mean
titer
gmt
geometr
mean
ratio
gmr
rate
seroconvers
seroprotect
measur
describ
random
treatment
group
exploratori
analysi
evalu
hai
immun
respons
subject
categor
seroneg
hai
titer
seroposit
hai
titer
base
prevaccin
titer
also
perform
gmt
twosid
confid
interv
ci
hai
mn
calcul
time
point
day
use
backtransform
mean
log
transform
hai
mn
titer
treatment
group
gmr
defin
backcalcul
mean
differ
postvaccinationprevaccin
log
transform
hai
titer
calcul
day
day
treatment
group
along
twosid
ci
use
tstatist
seroconvers
rate
day
percentag
subject
achiev
hai
seroprotect
mn
titer
day
correspond
twosid
ci
calcul
confid
interv
point
estim
obtain
use
clopperpearson
exact
method
seroconvers
defin
prevaccin
titer
postvaccin
titer
prevaccin
titer
minimum
fourfold
rise
postvaccin
hai
antibodi
titer
part
b
analysi
ae
experienc
overal
summar
treatment
group
incid
subject
one
vaccin
relat
ae
sever
lifethreaten
ae
sae
unsolicit
ae
se
twosid
pvalu
base
cochranarmitag
trend
test
incid
dose
applic
se
summar
treatment
group
vaccin
subject
count
per
categori
use
event
highest
sever
incid
sever
part
use
total
vaccin
cohort
cochranarmitag
trend
test
use
evalu
differ
across
group
subject
count
per
advers
event
categori
event
highest
sever
use
subject
experienc
multipl
event
total
subject
enrol
part
part
b
singl
site
mexico
subject
random
treatment
part
subject
vaccin
placebo
subject
vaccin
g
g
g
influenza
vlp
vaccin
respect
day
two
subject
random
receiv
g
vlp
dose
administ
g
vlp
dose
error
subject
receiv
treatment
dose
second
vaccin
analyz
accord
treatment
receiv
g
vlp
second
treatment
dose
administ
day
subject
placebo
g
g
g
influenza
vlp
vaccin
group
respect
subject
complet
studi
day
subject
random
treatment
part
b
subject
receiv
placebo
total
includ
one
subject
receiv
two
dose
placebo
count
twice
anoth
subject
receiv
dose
placebo
vlp
vaccin
subject
receiv
influenza
vlp
vaccin
dose
g
ha
protein
day
subject
complet
studi
day
fig
mean
age
subject
part
year
subject
male
femal
respect
part
b
mean
age
subject
year
male
femal
greater
subject
part
hispan
origin
demograph
characterist
vlp
vaccin
group
placebo
group
gener
compar
provid
tabl
part
studi
se
ie
select
inject
site
system
reaction
record
subject
symptom
diari
period
follow
vaccin
suffici
inform
se
experienc
subject
avail
part
studi
assum
safeti
result
would
compar
part
b
symptom
diari
use
part
b
solicit
event
report
subject
placebo
group
subject
g
g
g
vlp
vaccin
dosag
group
respect
tabl
result
cochranarmitag
trend
test
suggest
doserel
increas
incid
se
p
might
expect
primarili
attribut
inject
site
event
local
pain
swell
tender
red
report
subject
higher
vlp
dose
group
g
g
compar
placebo
g
vlp
group
follow
vaccin
fig
overal
major
local
ae
mild
sever
howev
moder
greater
local
inject
site
reaction
pain
tender
red
swell
also
show
dosetrend
cochranarmitag
test
vaccin
data
shown
differ
placebo
vaccin
recipi
system
se
incid
fig
howev
dosetrend
incid
moder
sever
intens
observ
cough
vaccin
one
muscl
pain
vaccin
two
data
shown
like
inject
site
event
system
se
overal
gener
mild
sever
incid
ae
se
compar
across
treatment
group
subject
placebo
group
subject
g
g
g
vlp
dosag
group
respect
experienc
least
one
ae
day
follow
first
vaccin
tabl
ae
consid
relat
vaccin
report
subject
placebo
group
subject
g
g
g
vlp
dosag
group
respect
across
group
major
event
mild
moder
sever
total
vlptreat
subject
placebotr
subject
report
least
one
sever
life
threaten
ae
tabl
vlp
group
major
sever
event
associ
gastrointestin
nervou
system
disord
incid
system
organ
class
soc
disord
unrel
studi
vaccin
eleven
subject
experienc
sae
none
consid
relat
vaccin
incid
ae
part
b
studi
consist
part
compar
vlp
placebo
group
total
subject
placebo
group
subject
vlp
group
experienc
least
one
ae
vaccinerel
ae
report
subject
placebo
group
subject
vlp
group
tabl
major
event
treatment
group
mild
moder
sever
total
vlptreat
subject
placebotr
subject
report
least
one
sever
life
threaten
ae
event
primarili
sever
intens
ie
six
lifethreaten
unrel
vaccin
infrequ
report
vlp
placebo
recipi
across
soc
forti
subject
experienc
sae
none
consid
relat
vaccin
hai
respons
measur
subject
use
modifi
intentto
treat
popul
mitt
includ
subject
receiv
full
partial
dose
studi
treatment
preand
postvaccin
immunogen
data
protocol
violat
enrol
part
studi
immunogen
analysi
result
perprotocol
includ
mitt
subject
protocol
violat
mitt
popul
similar
baselin
day
hai
titer
similar
across
group
hai
gmt
cours
studi
subject
potenti
expos
viru
slight
increas
hai
gmt
placebo
group
observ
hai
gmt
baselin
compar
day
day
chang
statist
signific
ci
respons
overlap
hai
respons
vlp
group
significantli
higher
placebo
post
baselin
time
point
dosedepend
rise
day
hai
respons
evid
comparison
g
g
g
vlp
vaccin
group
increas
hai
gmt
g
vlp
group
g
vlp
group
statist
signific
tabl
second
immun
show
effect
hai
titer
g
g
vlp
vaccin
group
result
slight
increas
g
vlp
group
similarli
hai
gmr
indic
doserespons
relationship
mean
increas
day
g
g
g
vaccin
group
respect
addit
increas
rel
day
result
day
week
second
inject
except
g
vlp
group
hai
gmr
seroconvers
rate
day
rang
placebo
group
respect
g
g
g
vaccin
group
tabl
percentag
subject
hai
titer
seroprotect
rang
across
group
baselin
reach
respect
g
g
g
vlp
vaccin
group
day
tabl
ad
benefit
seen
either
seroconvers
seroprotect
second
dose
trial
conduct
second
wave
pandem
approxim
subject
preexist
measur
immun
hai
find
concert
pandem
influenza
vaccin
trial
thu
exploratori
analysi
perform
subject
measur
hai
titer
ie
hai
titer
baselin
seroneg
day
hai
seroprotect
seroconvers
rate
ident
seroneg
subject
g
g
g
vaccin
dose
group
respect
unlik
seroposit
subject
seroneg
subject
trend
toward
higher
gmt
dosag
level
follow
vaccin
suggest
seroneg
popul
whole
prime
first
vaccin
dose
boost
second
tabl
high
rate
seroconvers
seroprotect
achiev
seroneg
popul
one
inject
suggest
vlp
vaccin
highli
immunogen
microneutr
assay
demonstr
higher
gmt
overal
subset
sub
tabl
immun
respons
measur
hemagglutin
inhibit
assay
hai
ject
evalu
essenti
confirm
hai
find
although
doserespons
differ
signific
tabl
revers
cumul
distribut
hai
respons
part
perform
display
rang
individu
respons
singl
dose
fig
doserespons
relationship
vlp
dose
evid
greatest
differ
seen
low
g
two
higher
g
g
vlp
dose
addit
also
clear
signific
number
subject
placebo
group
hai
antibodi
current
clinic
studi
insect
cellderiv
pandem
influenza
vaccin
candid
prove
immunogen
welltoler
healthi
adult
midst
pandem
mexico
compar
safeti
immunogen
result
adult
administ
singl
inject
publish
strain
inactiv
subvirion
vaccin
current
studi
popul
rel
high
rate
preexist
immun
hai
titer
rate
novel
pandem
strain
baselin
pandem
strain
seroprotect
rate
report
australian
popul
consist
studi
found
measur
cross
reactiv
pandem
strain
studi
data
shown
suggest
strain
specif
immun
sera
sampl
occur
end
second
wave
mexico
data
suggest
novel
pandem
strain
exposur
establish
rel
high
rate
subject
high
hai
titer
gener
popul
short
period
time
strain
specif
provid
opportun
evalu
vlp
vaccin
immunogen
rel
popul
subanalysi
perform
evalu
immunogen
vaccin
seroneg
popul
measur
hai
titer
baselin
indic
vlp
vaccin
immunogen
shown
tabl
respons
popul
robust
indic
seroprotect
rate
achiev
singl
g
dose
extens
deploy
licens
vaccin
pandem
occur
immunogen
result
also
robust
immunogen
appear
translat
clinic
signific
level
vaccin
efficaci
especi
young
larg
studi
chines
school
children
immun
singl
g
dose
monoval
splitvirion
vaccin
result
estim
vaccin
effect
confid
interv
larg
multicent
casecontrol
studi
base
medic
practicebas
activ
surveil
medic
attend
cultureconfirm
pandem
influenzalik
ill
ili
multipl
european
countri
age
use
multi
tabl
immun
respons
measur
microneutr
assay
mn
paramet
ple
vaccin
estim
vaccin
efficaci
ci
adjuv
vaccin
achiev
vaccin
efficaci
children
accompani
high
rate
fever
local
side
effect
addit
studi
data
indic
hai
titer
correl
protect
announc
pandem
mexico
creat
public
health
crisi
initi
widespread
effort
manufactur
appropri
vaccin
licens
eggbas
vaccin
effect
defici
vaccin
avail
due
limit
manufactur
techniqu
hamper
effort
major
impact
diseas
incid
although
insect
cell
produc
vlp
vaccin
develop
manufactur
lot
insect
cell
recombin
vlp
influenza
vaccin
complet
week
releas
relev
sequenc
cdc
data
present
studi
indic
vaccin
highli
immunogen
even
seroneg
popul
welltoler
larg
placebocontrol
studi
expect
public
health
author
transmiss
highli
pathogen
pandem
viru
emerg
remain
threat
deliveri
effect
rapidli
avail
vaccin
continu
import
develop
prioriti
result
studi
suggest
insect
cell
deriv
vlp
develop
candid
influenza
vaccin
support
object
addit
clinic
trial
develop
evalu
influenza
vaccin
candid
antigen
manufactur
use
vlp
technolog
studi
sponsor
novavax
collabor
laboratorio
avimex
sa
de
cv
conduct
mexican
social
secur
institut
imss
mexican
author
acknowledg
support
receiv
consejo
nacion
de
ciencia
conacyt
mexico
